{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:28:15Z","timestamp":1778797695298,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451\\u201303\\u201365\/2024\\u201301\/200178"],"award-info":[{"award-number":["451\\u201303\\u201365\/2024\\u201301\/200178"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451\\u201303\\u201366\/2024\\u201303\/200178"],"award-info":[{"award-number":["451\\u201303\\u201366\/2024\\u201303\/200178"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.phrs.2025.108078","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T16:03:14Z","timestamp":1766678594000},"page":"108078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Plasma miR-150\u20135p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal study"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-6329","authenticated-orcid":false,"given":"Nemanja","family":"Garai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Madic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vukan","family":"Ivanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksa","family":"Palibrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Pesovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Brkusanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Basta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-556X","authenticated-orcid":false,"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-4077","authenticated-orcid":false,"given":"Dusanka","family":"Savic-Pavicevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2025.108078_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.phrs.2025.108078_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2025.108078_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5-6","key":"10.1016\/j.phrs.2025.108078_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.phrs.2025.108078_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.886625","article-title":"Corticosteroid treatment-resistance in myasthenia gravis","volume":"13","author":"Kaminski","year":"2022","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108078_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108078_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.phrs.2025.108078_bib9","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2025.108078_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/mus.20568","article-title":"Concentric-needle single-fiber electromyography for the diagnosis of myasthenia gravis","volume":"34","author":"Benatar","year":"2006","journal-title":"Muscle nerve"},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle nerve"},{"issue":"5","key":"10.1016\/j.phrs.2025.108078_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mus.24438","article-title":"Oral corticosteroid therapy and present disease status in myasthenia gravis","volume":"51","author":"Imai","year":"2015","journal-title":"Muscle nerve"},{"issue":"22","key":"10.1016\/j.phrs.2025.108078_bib13","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehq167","article-title":"Circulating microRNAs are new and sensitive biomarkers of myocardial infarction","volume":"31","author":"D'Alessandra","year":"2010","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.phrs.2025.108078_bib14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1349-7006.2010.01650.x","article-title":"Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis","volume":"101","author":"Kosaka","year":"2010","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/eurheartj\/ehq013","article-title":"Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans","volume":"31","author":"Wang","year":"2010","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.hlc.2014.01.001","article-title":"Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases","volume":"23","author":"Sayed","year":"2014","journal-title":"Heart lung Circ."},{"key":"10.1016\/j.phrs.2025.108078_bib17","first-page":"277","article-title":"Circulating miRNAs as Biomarker in Cancer, Recent results in cancer research","volume":"215","author":"Andersen","year":"2020","journal-title":"Fortschr. der Krebsforsch. Prog. dans Les. Rech. sur Le. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41420-020-00397-6","article-title":"A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients","volume":"7","author":"Dobrowolny","year":"2021","journal-title":"Cell death Discov."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib19","article-title":"Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy","volume":"14","author":"D'Abundo","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-025-02298-7","article-title":"Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment","volume":"24","author":"Lim","year":"2025","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2025.108078_bib21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2013.07.003","article-title":"The role of miRNA in inflammation and autoimmunity","volume":"12","author":"Singh","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2025.108078_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/dmd.115.067470","article-title":"MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy","volume":"44","author":"Yu","year":"2016","journal-title":"Drug Metab. Dispos. Biol. fate Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.phrs.2025.108078_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104388","article-title":"MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine","volume":"148","author":"Cavalcante","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108078_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2025.108078_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040740","article-title":"Towards personalized medicine in myasthenia gravis: role of circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p","volume":"11","author":"Beretta","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.phrs.2025.108078_bib28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.28177","article-title":"Short-term changes in serum miRNA levels and patient-reported clinical outcomes in myasthenia gravis","volume":"70","author":"Huang","year":"2024","journal-title":"Muscle nerve"},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.phrs.2025.108078_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16280","article-title":"M.G.C. Sub-committee, Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis","volume":"31","author":"Meisel","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"18","key":"10.1016\/j.phrs.2025.108078_bib31","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle nerve"},{"issue":"12","key":"10.1016\/j.phrs.2025.108078_bib33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108078_bib34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108078_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108078_bib36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle nerve"},{"key":"10.1016\/j.phrs.2025.108078_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108078_bib38","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","article-title":"Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis","volume":"41","author":"Smith","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2025.108078_bib39","doi-asserted-by":"crossref","first-page":"1502721","DOI":"10.3389\/fimmu.2024.1502721","article-title":"Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis","volume":"15","author":"Watanabe","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/biomethods\/bpz006","article-title":"Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers","volume":"4","author":"Dufourd","year":"2019","journal-title":"Biol. Methods Protoc."},{"issue":"2","key":"10.1016\/j.phrs.2025.108078_bib41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1515\/cclm-2019-0719","article-title":"Serum or plasma? An old question looking for new answers","volume":"58","author":"Plebani","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1105\/tpc.109.066001","article-title":"Real-time quantitative RT-PCR: design, calculations, and statistics","volume":"21","author":"Rieu","year":"2009","journal-title":"Plant Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153200","article-title":"Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs","volume":"11","author":"Shah","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2025.108078_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/s11103-012-9885-2","article-title":"miRDeepFinder: a miRNA analysis tool for deep sequencing of plant small RNAs","author":"Xie","year":"2012","journal-title":"Plant Mol. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.phrs.2025.108078_bib46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108078_bib47","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"key":"10.1016\/j.phrs.2025.108078_bib48","unstructured":"Team R.C., R: A language and environment for statistical computing., R Foundation for Statistical Computing, Vienna, Austria, 2025."},{"key":"10.1016\/j.phrs.2025.108078_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2025.108078_bib50","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study, The Lancet regional health","volume":"38","author":"Li","year":"2023","journal-title":"West. Pac."},{"issue":"3","key":"10.1016\/j.phrs.2025.108078_bib51","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JND-230210","article-title":"Detection of Autoantibodies Against the Acetylcholine Receptor, Evaluation of Commercially Available Methodologies: Fixed Cell-Based Assay, Radioimmunoprecipitation Assay and Enzyme-Linked Immunosorbent Assay1","volume":"11","author":"Diogenes","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib52","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108078_bib53","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.13510","article-title":"Circulating microRNAs as potential biomarkers in myasthenia gravis patients","volume":"1412","author":"Punga","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"D1","key":"10.1016\/j.phrs.2025.108078_bib55","doi-asserted-by":"crossref","first-page":"D129","DOI":"10.1093\/nar\/gkae1036","article-title":"miRNATissueAtlas 2025: an update to the uniformly processed and annotated human and mouse non-coding RNA tissue atlas","volume":"53","author":"Rishik","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2025.108078_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","article-title":"R. Le Panse, Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108078_bib57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","article-title":"Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies","volume":"5","author":"Pritchard","year":"2012","journal-title":"Cancer Prev. Res."},{"issue":"3","key":"10.1016\/j.phrs.2025.108078_bib58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cei\/uxad126","article-title":"Plasma circulating microRNAs associated with blood-based immune markers: a population-based study","volume":"215","author":"Leonard","year":"2024","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.phrs.2025.108078_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007405","article-title":"MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis","volume":"4","author":"Vasilescu","year":"2009","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.phrs.2025.108078_bib60","doi-asserted-by":"crossref","first-page":"E1782","DOI":"10.21037\/jtd.2016.12.80","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"8","author":"Wolfe","year":"2016","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5507\/bp.2019.009","article-title":"Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10","volume":"164","author":"Ao","year":"2020","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czechoslov."},{"issue":"17","key":"10.1016\/j.phrs.2025.108078_bib62","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1073\/pnas.0702409104","article-title":"miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cell.2007.07.021","article-title":"MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb","volume":"131","author":"Xiao","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.108078_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2015.11.001","article-title":"MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28\/B7 costimulatory pathway","volume":"172","author":"Sang","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.phrs.2025.108078_bib65","doi-asserted-by":"crossref","first-page":"1140813","DOI":"10.3389\/fonc.2023.1140813","article-title":"Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases","volume":"13","author":"Hu","year":"2023","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108078_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113842","article-title":"Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells","volume":"9","author":"Palagani","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2025.108078_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.rccan.2017.07.001","article-title":"Autoimmune disorders and multiple myeloma- two illustrative case reports and a literature review","author":"\u00c1vila","year":"2018","journal-title":"Rev. Colomb. De. Cancerol. \u00eda"},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends genetics TIG"},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2024.0069","article-title":"It is time to revisit miRNA therapeutics","volume":"35","author":"Corey","year":"2025","journal-title":"Nucleic Acid. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib70","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1373\/clinchem.2010.157198","article-title":"Analysis of circulating microRNA: preanalytical and analytical challenges","volume":"57","author":"McDonald","year":"2011","journal-title":"Clin. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2025.108078_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041561","article-title":"Comparing the MicroRNA spectrum between serum and plasma","volume":"7","author":"Wang","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2025.108078_bib72","article-title":"Differences in serum and plasma levels of microRNAs and their time-course changes after blood collection","volume":"39","author":"Wakabayashi","year":"2024","journal-title":"Pract. Lab. Med."},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc2867","article-title":"Genetic variation in microRNA networks: the implications for cancer research","volume":"10","author":"Ryan","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib74","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4161\/rna.8.4.16029","article-title":"Population differences in microRNA expression and biological implications","volume":"8","author":"Huang","year":"2011","journal-title":"RNA Biol."},{"issue":"8","key":"10.1016\/j.phrs.2025.108078_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081254","article-title":"Comprehensive characterization of platelet-enriched MicroRNAs as biomarkers of platelet activation","volume":"11","author":"Krammer","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2025.108078_bib76","series-title":"WHO\/DIL\/LAB\/99.1 Rev.2","article-title":"Use of anticoagulants in diagnostic laboratory investigations","author":"World Health Organization","year":"2002"},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib77","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/acn3.51706","article-title":"The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis","volume":"10","author":"Huang","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108078_bib78","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1038\/s41467-025-63750-2","article-title":"Platelet activation plays a pro-inflammatory role in myasthenia gravis","volume":"16","author":"Wen","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2025.108078_bib79","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1160\/TH12-11-0819","article-title":"CD4+ T cells in atherosclerosis: regulation by platelets","volume":"109","author":"Li","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2025.108078_bib80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fendo.2018.00074","article-title":"The Potential role of platelet-related micrornas in the development of cardiovascular events in high-risk populations, including diabetic patients: a review","volume":"9","author":"Pordzik","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108078_bib81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/CIRCRESAHA.111.300539","article-title":"Circulating microRNAs as novel biomarkers for platelet activation","volume":"112","author":"Willeit","year":"2013","journal-title":"Circ. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825005031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825005031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:44:16Z","timestamp":1778795056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825005031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":81,"alternative-id":["S1043661825005031"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108078","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma miR-150\u20135p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108078"}}